Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - The J.P. Morgan Healthcare Conference is emphasizing the importance of investing in women's health, with a series of panels dedicated to this topic [1][2] - Daré Bioscience, a leader in women's health innovation, is participating in the conference, highlighting its commitment to advancing therapies for women's health [1][3] Company Overview - Daré Bioscience is focused on developing innovative products for women's health, aiming to improve treatment options and outcomes in areas such as contraception, sexual health, and menopause [3] - The company has a diverse portfolio of product candidates, including XACIATO™, Ovaprene®, Sildenafil Cream, and DARE-HRT1, targeting various women's health issues [4] Recent Developments - Sabrina Martucci Johnson, CEO of Daré Bioscience, will speak at the conference about the potential for increased investment in women's health and the company's investigational products [2] - Daré has received two non-dilutive funding awards of approximately $10 million each in 2024 to support the development of a novel non-hormonal contraceptive and an HPV treatment [2] Recognition and Awards - Daré Bioscience has been recognized in the biopharmaceutical industry, with its leadership featured in notable lists such as Medicine Maker’s Power List and Endpoints News’ Women in Biopharma [5][6] - The company was ranked 1 in the Small Company category of the San Diego Business Journal’s 2023 Best Places to Work Awards [6]